Vol. 4 No. 3 (2023): Proceedings of the MGFA International Conference

MGFA International Conference Proceedings

• MGFA Meeting Proceedings: Editor's Introduction

  Carolina Barnett-Tapia, Kevin O'Connor, Richard J. Barohn, MD

  • PDF

• Myasthenia research over the last 50 years – a personal perspective

  Angela Vincent MBBS (Hon PhD Bergen) FRS FRCP FRCPath FMedSci

  • PDF

• Pharmacological treatment of Lambert-Eaton Myasthenic Syndrome

  Wisse Roelof Bakker, Linda Remijn-Nelissen, Kirsten Schimmel, Martijn Tannemaat, Jan Verschuuren, Teun van Gelder

  • PDF

• Challenges managing myasthenia gravis: an international perspective

  Carolina Barnett, Fatmah Alzahmi, Dong Dong, Jeannine Heckman, Valeria Salutto, Ha Young Shin

  • PDF

• Congenital myasthenic syndromes: beta adrenergic receptor agonist treatment

  David Beeson

  • PDF

• Exercise Training for autoimmune myasthenia gravis: A review of safety and effectiveness based on existing literature

  Simone Birnbaum PhD BPhty, Tarek Sharshar Pr, Jean-Yves Hogrel PhD

  • PDF

• MiR-146a in myasthenia gravis thymus: from uncontrolled innate immunity to B cell-mediated autoimmunity MiR-146a in MG thymus

  Paola Cavalcante, Maria Cristina Tarasco, Nicola Iacomino, Carlo Antozzi, Renato Mantegazza

  • PDF

• Biomarker Development, Methodological Challenges

  Gary R. Cutter PhD

  • PDF

• Diagnostic challenges in myasthenia gravis: a clinical approach

  Robert H. P. de Meel, MD MA PhD

  • PDF

• The mechanisms of immunopathology underlying B cell depletion therapy-mediated remission and relapse in patients with MuSK MG Immune mechanisms of MuSK MG

  Kevin OConnor, Miriam Fichtner

  • PDF

• Refractory myasthenia gravis: the more we learn, the less we know.

  Ali A. Habib

  • PDF

• Complement inhibition in Myasthenia – from basics to RCT data

  Saiju Jacob

  • PDF

• Congenital Myasthenic Syndromes A paradigm shift

  Ricardo Maselli

  • PDF

• A Promising Antigen-specific Immunotherapy for the Treatment of Myasthenia Gravis

  Eleni Ntoukaki , Vasiliki Baltatzidou , Konstantinos Lazaridis

  • PDF

• Targeting the safety factor for neuromuscular transmission to treat myasthenia gravis Safety factor for neuromuscular transmission

  Lorenzo, William Phillips

  • PDF

• Assay Development and Measurement of Autoantibody-Mediated Complement Activity in Myasthenia Gravis

  Abeer Obaid

  • PDF

• MuSK-CAART: A novel precision cellular therapy for muscle-specific tyrosine kinase myasthenia gravis Precision cellular therapy for MuSK myasthenia gravis

  Aimee Payne, Sangwook Oh

  • PDF

• Circulating microRNA in Myasthenia gravis (MG)

  Anna Punga, Tanel Punga

  • PDF

• Symptomatic, pharmacological treatment of myasthenia gravis.

  Linda Remijn-Nelissen, Wisse R. Bakker, Teun van Gelder, Martijn R. Tannemaat, Jan J.G.M. Verschuuren

  • PDF

• Identification of Rare Membrane Antigen Specific Human B Cells

  nicholas sanderson

  • PDF

• Corticosteroids in Generalized Autoimmune Myasthenia Gravis: A Narrative Review

  Tarek Sharshar, Aurélien Mazeraud, Simone Birnbaum

  • PDF

• Pediatric Myasthenia Gravis As presented at the MGFA 14th International Conference in Miami, Florida on May 11, 2022

  Emmanuelle Tiongson MD

  • PDF